Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OMED-3
- Development stage
- Preclinical
- Lead developer
- Onena Medicines
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Parenteral
01
Overview
OMED-3 is a preclinical-stage antibody-based therapeutic candidate being developed by Onena Medicines for the treatment of obesity and diabetes. It is part of a pipeline of medicines designed to target Dual Secreted Inhibitory Proteins (DSIPs), a proprietary class of secreted proteins identified by Onena that regulate metabolic and growth signaling pathways. OMED-3 specifically targets DSIP#3 to modulate metabolic processes associated with weight management and glucose regulation. By neutralizing this secreted factor, the drug aims to restore or enhance metabolic signaling that is disrupted in metabolic diseases.
02
Targets
SMAD (SMAD family)
Beyond the preview
Go deeper on OMED-3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OMED-3.